WO2010033247A3 - Reduced size self-delivering rnai compounds - Google Patents
Reduced size self-delivering rnai compounds Download PDFInfo
- Publication number
- WO2010033247A3 WO2010033247A3 PCT/US2009/005247 US2009005247W WO2010033247A3 WO 2010033247 A3 WO2010033247 A3 WO 2010033247A3 US 2009005247 W US2009005247 W US 2009005247W WO 2010033247 A3 WO2010033247 A3 WO 2010033247A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reduced size
- rnai compounds
- size self
- delivering rnai
- gene silencing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009801464922A CN102405286A (en) | 2008-09-22 | 2009-09-22 | Reduced size self-delivering rnai compounds |
CA2743981A CA2743981C (en) | 2008-09-22 | 2009-09-22 | Reduced size self-delivering rnai compounds |
JP2011527828A JP6209309B2 (en) | 2008-09-22 | 2009-09-22 | Reduced size RNAi compound for self delivery |
EP17200910.2A EP3336188B1 (en) | 2008-09-22 | 2009-09-22 | Reduced size self-delivering rnai compounds |
AU2009293658A AU2009293658A1 (en) | 2008-09-22 | 2009-09-22 | Reduced size self-delivering RNAi compounds |
CN201711334248.1A CN108165548B (en) | 2008-09-22 | 2009-09-22 | Reduced size self-delivering RNAi compounds |
US13/120,342 US8796443B2 (en) | 2008-09-22 | 2009-09-22 | Reduced size self-delivering RNAi compounds |
EP09789351.5A EP2340310B1 (en) | 2008-09-22 | 2009-09-22 | Reduced size self-delivering rnai compounds |
IL211863A IL211863A0 (en) | 2008-09-22 | 2011-03-22 | Reduced size self-delivering rnai compounds |
US13/069,780 US10041073B2 (en) | 2008-09-22 | 2011-03-23 | Reduced size self-delivering RNAi compounds |
US14/278,900 US9175289B2 (en) | 2008-09-22 | 2014-05-15 | Reduced size self-delivering RNAi compounds |
US14/866,681 US10774330B2 (en) | 2008-09-22 | 2015-09-25 | Reduced size self-delivering RNAI compounds |
US16/022,652 US10876119B2 (en) | 2008-09-22 | 2018-06-28 | Reduced size self-delivering RNAI compounds |
US16/934,864 US20210147849A1 (en) | 2008-09-22 | 2020-07-21 | Reduced size self-delivering rnai compounds |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19295408P | 2008-09-22 | 2008-09-22 | |
US61/192,954 | 2008-09-22 | ||
US14994609P | 2009-02-04 | 2009-02-04 | |
US61/149,946 | 2009-02-04 | ||
US22403109P | 2009-07-08 | 2009-07-08 | |
US61/224,031 | 2009-07-08 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/120,342 A-371-Of-International US8796443B2 (en) | 2008-09-22 | 2009-09-22 | Reduced size self-delivering RNAi compounds |
US13/069,780 Continuation-In-Part US10041073B2 (en) | 2008-09-22 | 2011-03-23 | Reduced size self-delivering RNAi compounds |
US14/278,900 Continuation US9175289B2 (en) | 2008-09-22 | 2014-05-15 | Reduced size self-delivering RNAi compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010033247A2 WO2010033247A2 (en) | 2010-03-25 |
WO2010033247A3 true WO2010033247A3 (en) | 2010-06-03 |
Family
ID=41445574
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/005251 WO2010033248A2 (en) | 2008-09-22 | 2009-09-22 | Neutral nanotransporters |
PCT/US2009/005247 WO2010033247A2 (en) | 2008-09-22 | 2009-09-22 | Reduced size self-delivering rnai compounds |
PCT/US2009/005246 WO2010033246A1 (en) | 2008-09-22 | 2009-09-22 | Rna interference in skin indications |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/005251 WO2010033248A2 (en) | 2008-09-22 | 2009-09-22 | Neutral nanotransporters |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/005246 WO2010033246A1 (en) | 2008-09-22 | 2009-09-22 | Rna interference in skin indications |
Country Status (8)
Country | Link |
---|---|
US (12) | US10138485B2 (en) |
EP (5) | EP2342340A1 (en) |
JP (5) | JP2012502991A (en) |
CN (2) | CN108165548B (en) |
AU (1) | AU2009293658A1 (en) |
CA (4) | CA2753338A1 (en) |
IL (1) | IL211863A0 (en) |
WO (3) | WO2010033248A2 (en) |
Families Citing this family (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100949791B1 (en) * | 2007-12-18 | 2010-03-30 | 이동기 | Novel siRNA Structure for Minimizing Off-target Effects and Relaxing Saturation of RNAi Machinery and the Use Thereof |
JP2011507862A (en) * | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scarring |
US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
US8946172B2 (en) * | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
AU2009275387B2 (en) | 2008-08-25 | 2010-07-08 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
WO2010033248A2 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
ES2629630T3 (en) * | 2008-12-04 | 2017-08-11 | Curna, Inc. | Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO |
WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
WO2011109248A1 (en) | 2010-03-02 | 2011-09-09 | Hapten Pharmaceuticals, Llc | Effective sensitizing dose of a gelled immunomodulating topical composition |
WO2011109698A1 (en) * | 2010-03-04 | 2011-09-09 | Rxi Pharmaceuticals Corporation | Formulations and methods for targeted delivery to phagocyte cells |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
WO2011119871A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Phrmaceuticals Corporation | Rna interference in ocular indications |
JP6060071B2 (en) | 2010-03-24 | 2017-01-11 | アールエックスアイ ファーマシューティカルズ コーポレーション | RNA interference in skin and fibrosis applications |
EP2550000A4 (en) * | 2010-03-24 | 2014-03-26 | Advirna Inc | Reduced size self-delivering rnai compounds |
US9145556B2 (en) | 2010-04-13 | 2015-09-29 | Life Technologies Corporation | Compositions and methods for inhibition of nucleic acids function |
CN103328633B (en) | 2010-10-22 | 2018-07-10 | 成均馆大学校产学协力团 | Induce nucleic acid molecules of RNA interference and application thereof |
CN103260702B (en) | 2010-10-28 | 2018-07-27 | 帕西拉制药有限公司 | The sustained release preparation of non-steroid anti-inflammatory drug |
WO2012106508A1 (en) | 2011-02-02 | 2012-08-09 | Pfizer Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
WO2012110457A2 (en) * | 2011-02-14 | 2012-08-23 | Santaris Pharma A/S | Compounds for the modulation of osteopontin expression |
SG193923A1 (en) | 2011-03-29 | 2013-11-29 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of tmprss6 gene |
US8802839B2 (en) | 2011-07-15 | 2014-08-12 | Fibrogen, Inc. | Connective tissue growth factor antisense oligonucleotides |
SI3366775T1 (en) * | 2011-11-18 | 2022-09-30 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
US9850541B2 (en) * | 2011-12-19 | 2017-12-26 | Valley Health System | Methods and kits for detecting subjects at risk of having cancer |
KR20220051197A (en) | 2012-05-17 | 2022-04-26 | 익스텐드 바이오사이언시즈, 인크. | Carriers for improved drug delivery |
CN104755620B (en) * | 2012-05-22 | 2018-03-02 | 奥利克斯医药有限公司 | Nucleic acid molecules of induction RNA interference with intracellular penetration capacity and application thereof |
US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
EP2948134B1 (en) | 2013-01-24 | 2020-03-04 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mtor inhibitors |
WO2014164802A1 (en) | 2013-03-11 | 2014-10-09 | The Johns Hopkins University | Influenza-activated constructs and methods of use thereof |
PL230602B1 (en) | 2013-04-04 | 2018-11-30 | Centrum Badan Molekularnych I Makromolekularnych Polskiej Akademii Nauk | (E)3-aryl-3-oxoprop-1-enyl-2-phosphonic acid and its derivatives - their manufacture and their use |
CN105452463B (en) | 2013-05-22 | 2019-06-21 | 阿尔尼拉姆医药品有限公司 | TMPRSS6 IRNA composition and its application method |
PL223918B1 (en) | 2013-05-28 | 2016-11-30 | Centrum Badań Molekularnych i Makromolekularnych Polskiej Akademii Nauk | 3-Aryl-2-phosphoryl substituted indanones and a method for their preparation |
EP3027222A1 (en) | 2013-07-31 | 2016-06-08 | QBI Enterprises Ltd. | Sphingolipid-polyalkylamine-oligonucleotide compounds |
CN113151180A (en) | 2013-12-02 | 2021-07-23 | 菲奥医药公司 | Immunotherapy of cancer |
JP6883987B2 (en) * | 2013-12-04 | 2021-06-09 | フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. | Methods for wound healing procedures utilizing chemically modified oligonucleotides |
UA118278C2 (en) | 2014-01-10 | 2018-12-26 | Глаксосмітклайн Інтеллектьюел Проперті (№ 2) Лімітед | Hydroxy formamide derivatives and their use |
JPWO2015108162A1 (en) | 2014-01-17 | 2017-03-23 | 協和発酵キリン株式会社 | Nucleic acids that suppress β2GPI expression |
WO2015123551A1 (en) | 2014-02-13 | 2015-08-20 | Du Luqin | Microrna composition for the treatment of neuroblastoma |
DK3119887T3 (en) * | 2014-03-20 | 2019-05-20 | Oommen Varghese | Improved short interfering ribonucleic acid molecules |
US11318206B2 (en) | 2014-03-28 | 2022-05-03 | Aposense Ltd | Compounds and methods for trans-membrane delivery of molecules |
AU2015237746B2 (en) * | 2014-03-28 | 2020-01-30 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
EP3733856A1 (en) | 2014-04-18 | 2020-11-04 | University of Massachusetts | Exosomal loading using hydrophobically modified oligonucleotides |
CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
CA2947619A1 (en) * | 2014-05-01 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules |
WO2015188197A2 (en) * | 2014-06-06 | 2015-12-10 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
RU2017101023A (en) | 2014-06-16 | 2018-07-16 | Торэй Индастриз, Инк. | KIT OR DEVICE FOR DETECTING STOMACH CANCER AND DETECTION METHOD |
KR20230037676A (en) | 2014-09-05 | 2023-03-16 | 피오 파마슈티칼스 코프. | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
RU2020108189A (en) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | COMPOSITIONS AND METHODS OF TREATMENT OF LATERAL AMYOTROPHIC SCLEROSIS (ALS) |
CN107207556B (en) | 2014-11-14 | 2020-12-08 | 沃雅戈治疗公司 | Regulatory polynucleotides |
WO2016085852A1 (en) | 2014-11-24 | 2016-06-02 | Alnylam Pharmaceuticals, Inc. | Tmprss6 irna compositions and methods of use thereof |
WO2016090173A1 (en) * | 2014-12-03 | 2016-06-09 | Rxi Pharmaceuticals Corporation | Methods for the treatment of alopecia areata utilizing gene modulation approaches |
WO2016161388A1 (en) * | 2015-04-03 | 2016-10-06 | University Of Massachusetts | Fully stabilized asymmetric sirna |
ES2808750T3 (en) | 2015-04-03 | 2021-03-01 | Univ Massachusetts | Oligonucleotide compounds targeting huntingtin mRNA |
ES2901455T3 (en) | 2015-04-03 | 2022-03-22 | Univ Massachusetts | Oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders |
KR20180026739A (en) * | 2015-07-06 | 2018-03-13 | 알엑스아이 파마슈티칼스 코포레이션 | A nucleic acid molecule targeting superoxide dismutase 1 (SOD1) |
US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
CA2995110A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
US11021707B2 (en) * | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
US10059949B2 (en) | 2015-11-16 | 2018-08-28 | Olix Pharmaceuticals, Inc. | Treatment of age-related macular degeneration using RNA complexes that target MYD88 or TLR3 |
EP3386517A4 (en) * | 2015-12-08 | 2019-08-07 | Solstice Biologics, Ltd. | Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate |
JP2019503394A (en) | 2016-01-31 | 2019-02-07 | ユニバーシティ・オブ・マサチューセッツUniversity Of Massachusetts | Branched oligonucleotide |
CN108779464B (en) | 2016-02-02 | 2022-05-17 | 奥利克斯医药有限公司 | Treatment of angiogenesis-related diseases using RNA complexes targeting ANGPT2 and PDGFB |
CN108779463B (en) | 2016-02-02 | 2022-05-24 | 奥利克斯医药有限公司 | Treatment of atopic dermatitis and asthma using RNA complexes targeting IL4R α, TRPA1, or F2RL1 |
MA45328A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF |
MA45349A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | EGFR NUCLEIC ACIDS AND THEIR USES |
MA45470A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | KRAS NUCLEIC ACIDS AND THEIR USES |
MA45469A (en) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | BETA-CATENIN NUCLEIC ACIDS AND THEIR USES |
KR102339886B1 (en) | 2016-04-11 | 2021-12-17 | 올릭스 주식회사 | Method of treatment of idiopathic pulmonary fibrosis using RNA complexes targeting connective tissue growth factor |
KR101916652B1 (en) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | Compounds improving RNA interference of small interfering RNA and use thereof |
WO2018022927A1 (en) * | 2016-07-27 | 2018-02-01 | BioAxone BioSciences, Inc. | TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICS |
WO2018031933A2 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
US11246905B2 (en) | 2016-08-15 | 2022-02-15 | President And Fellows Of Harvard College | Treating infections using IdsD from Proteus mirabilis |
US20190202855A1 (en) * | 2016-08-17 | 2019-07-04 | Sukumar Sakamuri | Polynucleotide constructs |
CN106244590B (en) * | 2016-08-18 | 2019-10-01 | 广州市锐博生物科技有限公司 | Modified siRNA molecule, RNAi molecule mixture and its application |
IT201600093825A1 (en) * | 2016-09-19 | 2018-03-19 | Fondazione St Italiano Tecnologia | Pharmaceutical composition of miRNA and its therapeutic uses. |
US11260134B2 (en) | 2016-09-29 | 2022-03-01 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex having overhang |
CN108070610B (en) * | 2016-11-08 | 2021-11-09 | 中国科学院分子植物科学卓越创新中心 | Plant genome fixed-point knocking-in method |
CN109983013A (en) | 2016-11-18 | 2019-07-05 | 帕西拉制药有限公司 | Meloxicam zinc complexes particle multivesicular liposome preparation and preparation method thereof |
CN106498072B (en) * | 2016-11-24 | 2019-09-10 | 青岛千卓分子生物科技有限公司 | The guard method and its application of exogenous DNA internal standard compound in a kind of liquid form product |
CA3049402A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
CA3049640A1 (en) | 2017-01-09 | 2018-07-12 | Aposense Ltd. | Compounds and methods for trans-membrane delivery of molecules |
JP2020505025A (en) | 2017-01-13 | 2020-02-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Pluripotent cells modified by immunotechnology |
WO2018146557A2 (en) | 2017-02-10 | 2018-08-16 | Dong Ki Lee | Long double-stranded rna for rna interference |
JPWO2018164186A1 (en) | 2017-03-09 | 2020-01-09 | 協和キリン株式会社 | Nucleic acids that suppress MASP2 expression |
EP4029942A1 (en) | 2017-04-05 | 2022-07-20 | Silence Therapeutics GmbH | Products and compositions |
JP2020518258A (en) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | Amyotrophic lateral sclerosis (ALS) treatment composition and method |
WO2018221649A1 (en) | 2017-05-31 | 2018-12-06 | 協和発酵キリン株式会社 | Apcs-expression-suppressing nucleic acids |
US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
CN111201024A (en) * | 2017-08-07 | 2020-05-26 | 菲奥医药公司 | Chemically modified oligonucleotides |
AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
BR112020009663A2 (en) | 2017-11-17 | 2020-11-10 | Iovance Biotherapeutics, Inc. | method for the expansion of tumor infiltrating lymphocytes (tils) in a therapeutic population of tils, method for the treatment of an individual with cancer, composition |
JP2021503885A (en) | 2017-11-22 | 2021-02-15 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood |
SG11202005022YA (en) | 2017-12-06 | 2020-06-29 | Avidity Biosciences Inc | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
WO2019136456A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
US20210000858A1 (en) * | 2018-03-02 | 2021-01-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Stem cell-derived exosomes for the treatment of corneal scarring |
US11648260B2 (en) | 2018-03-29 | 2023-05-16 | Technion Research And Development Foundation Limitted | Vesicles comprising a PTEN inhibitor and uses of same |
EP3784258A4 (en) * | 2018-04-25 | 2022-08-10 | University of Massachusetts | Artificial exosome composition and related methods |
US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
CA3103963A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
CA3109133A1 (en) | 2018-08-10 | 2020-02-13 | University Of Massachusetts | Modified oligonucleotides targeting snps |
EP3840759A4 (en) * | 2018-08-23 | 2022-06-01 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
WO2020096989A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
EP3877512A2 (en) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
MX2021004775A (en) | 2018-11-05 | 2021-06-08 | Iovance Biotherapeutics Inc | Expansion of tils utilizing akt pathway inhibitors. |
CN113272421A (en) | 2018-11-05 | 2021-08-17 | 艾欧凡斯生物治疗公司 | Method for generating tumor infiltrating lymphocytes and use thereof in immunotherapy |
TW202028222A (en) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Modulators of foxp3 expression |
KR20210098477A (en) | 2018-11-30 | 2021-08-10 | 쿄와 기린 가부시키가이샤 | Nucleic Acid Complex |
EP3898949A1 (en) | 2018-12-19 | 2021-10-27 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
MX2021010288A (en) | 2019-03-01 | 2021-09-23 | Iovance Biotherapeutics Inc | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof. |
WO2020181107A1 (en) * | 2019-03-05 | 2020-09-10 | MiRagen Therapeutics, Inc. | Microrna mimics and uses thereof |
US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
JP2022540012A (en) | 2019-06-26 | 2022-09-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Natural killer (NK) cells with SIRPα silenced |
KR20220110749A (en) * | 2019-11-06 | 2022-08-09 | 알닐람 파마슈티칼스 인코포레이티드 | extrahepatic transmission |
US20230002766A1 (en) | 2019-11-08 | 2023-01-05 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy |
CA3161104A1 (en) | 2019-12-11 | 2021-06-17 | Cecile Chartier-Courtaud | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
EP4085136A1 (en) | 2019-12-31 | 2022-11-09 | Phio Pharmaceuticals Corp. | Chemically modified oligonucleotides with improved systemic delivery |
CN115666589A (en) | 2020-03-19 | 2023-01-31 | 艾维迪提生物科学公司 | Compositions and methods for treating facioscapulohumeral muscular dystrophy |
TW202208617A (en) | 2020-05-04 | 2022-03-01 | 美商艾歐凡斯生物治療公司 | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
CA3177413A1 (en) | 2020-05-04 | 2021-11-11 | Michelle SIMPSON-ABELSON | Selection of improved tumor reactive t-cells |
US11459567B2 (en) | 2020-06-24 | 2022-10-04 | Patricia Virginia Elizalde | Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer |
JP2023546359A (en) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
CN112263587B (en) * | 2020-10-23 | 2022-08-30 | 河北仁博科技有限公司 | Application of miR-3065-5p in preparation of medicine for preventing and/or treating renal fibrosis |
JP2024501452A (en) | 2020-12-11 | 2024-01-12 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of cancer patients with tumor-infiltrating lymphocyte therapy in combination with BRAF inhibitors and/or MEK inhibitors |
WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
JP2024500403A (en) | 2020-12-17 | 2024-01-09 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Treatment of cancer with tumor-infiltrating lymphocytes |
JP2024515189A (en) | 2021-04-19 | 2024-04-05 | アイオバンス バイオセラピューティクス,インコーポレイテッド | Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy - Patents.com |
BR112023022284A2 (en) | 2021-04-26 | 2023-12-26 | Alnylam Pharmaceuticals Inc | COMPOSITIONS OF TRANSMEMBRANE PROTEASE IRNA, SERINE 6 (TMPRSS6) AND METHODS OF USE THEREOF |
AU2022299169A1 (en) | 2021-06-23 | 2024-02-08 | Beth Israel Deaconess Medical Center, Inc. | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
WO2023015264A1 (en) | 2021-08-04 | 2023-02-09 | Phio Pharmaceuticals Corp. | Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides |
KR20240041973A (en) | 2021-08-04 | 2024-04-01 | 피오 파마슈티칼스 코프. | Chemically modified oligonucleotides |
AR127482A1 (en) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
CN114767703B (en) * | 2022-06-20 | 2022-09-02 | 山东恺悌生物制品有限公司 | Application of miR-4311 mimic in preparation of lung cancer treatment drug |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005079533A2 (en) * | 2004-02-17 | 2005-09-01 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
WO2005097992A2 (en) * | 2004-04-01 | 2005-10-20 | Dharmacon, Inc. | Modified polynucleotides for reducing off-target effects in rna interference |
WO2006019430A2 (en) * | 2004-04-20 | 2006-02-23 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
WO2006039656A2 (en) * | 2004-10-01 | 2006-04-13 | Novartis Vaccines And Diagnostics Inc. | Modified small interfering rna molecules and methods of use |
WO2006113679A2 (en) * | 2005-04-15 | 2006-10-26 | Board Of Regents, The University Of Texas System | Delivery of sirna by neutral lipid compositions |
US20080020990A1 (en) * | 2003-05-30 | 2008-01-24 | Nippon Shinyaku Co., Ltd. | Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same |
WO2008036825A2 (en) * | 2006-09-22 | 2008-03-27 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
WO2009020344A2 (en) * | 2007-08-06 | 2009-02-12 | Postech Acad Ind Found | Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same |
WO2009078685A2 (en) * | 2007-12-18 | 2009-06-25 | Dong Ki Lee | Novel sirna structure for minimizing off-target effects and relaxing saturation of rnai machinery and the use thereof |
Family Cites Families (438)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
DE2010115A1 (en) | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Process for the production of micro-granules |
JPS523342B2 (en) | 1972-01-26 | 1977-01-27 | ||
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4201860A (en) | 1978-05-09 | 1980-05-06 | Bristol-Myers Company | Purine derivatives |
US4384975A (en) | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
US4389330A (en) | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US4415732A (en) | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US4426330A (en) | 1981-07-20 | 1984-01-17 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
JPS60100516A (en) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
US5700785A (en) | 1984-07-11 | 1997-12-23 | Temple University - Of The Commonwealth System Of Higher Education | 3'-deoxy or 3'-O-substituted-2',5'-oligoadenylates as antiviral agents |
US5643889A (en) | 1984-07-11 | 1997-07-01 | Temple University-Of The Commonwealth System Of Pennsylvania | Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
DE3788914T2 (en) | 1986-09-08 | 1994-08-25 | Ajinomoto Kk | Compounds for cleaving RNA at a specific position, oligomers used in the preparation of these compounds and starting materials for the synthesis of these oligomers. |
US6005094A (en) | 1986-10-28 | 1999-12-21 | Genta Incorporated | Oligonucleotide analogues having improved stability at acid pH |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (en) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | MODIFIED OLIGONUCLEOTIDS |
EP0348458B1 (en) | 1987-11-30 | 1997-04-09 | University Of Iowa Research Foundation | Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5750666A (en) | 1988-05-26 | 1998-05-12 | Competitve Technologies, Inc. | Polynucleotide phosphorodithioate compounds |
US5149782A (en) | 1988-08-19 | 1992-09-22 | Tanox Biosystems, Inc. | Molecular conjugates containing cell membrane-blending agents |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
ATE133087T1 (en) | 1989-05-04 | 1996-02-15 | Southern Res Inst | ENCAPSULATION PROCESS |
US5051257A (en) | 1989-05-09 | 1991-09-24 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
US5162115A (en) | 1989-05-09 | 1992-11-10 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
ZA902710B (en) | 1989-05-22 | 1991-12-24 | Univ Georgia Res Found | Enzyme luminescence assay |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5227170A (en) | 1989-06-22 | 1993-07-13 | Vestar, Inc. | Encapsulation process |
JPH0383914A (en) | 1989-08-18 | 1991-04-09 | W R Grace & Co | Drug carrier |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5356633A (en) | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5527528A (en) | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
WO1991006556A1 (en) | 1989-10-24 | 1991-05-16 | Gilead Sciences, Inc. | 2' modified oligonucleotides |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
US5495009A (en) | 1989-10-24 | 1996-02-27 | Gilead Sciences, Inc. | Oligonucleotide analogs containing thioformacetal linkages |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5914396A (en) | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
US6358931B1 (en) | 1990-01-11 | 2002-03-19 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating RNA |
US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US5514786A (en) | 1990-01-11 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Compositions for inhibiting RNA activity |
AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5386023A (en) | 1990-07-27 | 1995-01-31 | Isis Pharmaceuticals | Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling |
WO1992002258A1 (en) | 1990-07-27 | 1992-02-20 | Isis Pharmaceuticals, Inc. | Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US6262241B1 (en) | 1990-08-13 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Compound for detecting and modulating RNA activity and gene expression |
JPH0813274B2 (en) | 1990-08-13 | 1996-02-14 | アイシス・ファーマシューティカルス・インコーポレーテッド | Sugar modified oligonucleotides for detecting and modulating gene expression |
WO1992003464A1 (en) | 1990-08-28 | 1992-03-05 | Microprobe Corporation | Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule |
US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
WO1992005186A1 (en) | 1990-09-20 | 1992-04-02 | Gilead Sciences | Modified internucleoside linkages |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
CA2082951C (en) | 1991-03-15 | 1999-12-21 | Robert M. Platz | Pulmonary administration of granulocyte colony stimulating factor |
WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
JP3220180B2 (en) | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | Drug-containing protein-bound liposomes |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
DK51092D0 (en) | 1991-05-24 | 1992-04-15 | Ole Buchardt | OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF |
US5770209A (en) | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
US5214135A (en) | 1991-08-30 | 1993-05-25 | Chemgenes Corporation | N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides |
US7384634B2 (en) | 1991-08-30 | 2008-06-10 | University Of South Florida | Connective tissue growth factor |
US5525719A (en) | 1991-08-30 | 1996-06-11 | Chemgenes Corporation | N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5661134A (en) | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
US5599797A (en) | 1991-10-15 | 1997-02-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5607923A (en) | 1991-10-15 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5856455A (en) | 1991-12-24 | 1999-01-05 | Isis Pharmaceuticals, Inc. | Gapped 2'-modified oligonucleotides |
NZ245720A (en) | 1992-01-22 | 1995-12-21 | Hoechst Ag | Oligonucleotide analogues; use as gene expression inhibitor or dna probe |
US6113946A (en) | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5817781A (en) | 1992-06-01 | 1998-10-06 | Gilead Sciences, Inc. | Modified internucleoside linkages (II) |
EP0577558A2 (en) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates |
US6172208B1 (en) | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
US6346614B1 (en) | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
US5583020A (en) | 1992-11-24 | 1996-12-10 | Ribozyme Pharmaceuticals, Inc. | Permeability enhancers for negatively charged polynucleotides |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
JP3351476B2 (en) | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | Phospholipid derivatives and liposomes containing the same |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
EP0693123A1 (en) | 1993-03-31 | 1996-01-24 | HYBRIDON, Inc. | Modified oligonucleotides having improved anti-influenza activity |
ATE160572T1 (en) | 1993-03-31 | 1997-12-15 | Sanofi Sa | OLIGONUCLEOTIDES WITH AMIDE CHAINS THAT USE PHOSPHOESTER CHAINS |
ES2128535T3 (en) | 1993-05-12 | 1999-05-16 | Novartis Ag | NUCLEOSIDES AND OLIGONUCLEOTIDES WITH 2'-ETER GROUPS. |
FR2705099B1 (en) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Phosphorothioate triester oligonucleotides and process for their preparation. |
US6015886A (en) | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
US5428149A (en) | 1993-06-14 | 1995-06-27 | Washington State University Research Foundation | Method for palladium catalyzed carbon-carbon coulping and products |
US5580972A (en) | 1993-06-14 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | Purine nucleoside modifications by palladium catalyzed methods |
US5534259A (en) | 1993-07-08 | 1996-07-09 | Liposome Technology, Inc. | Polymer compound and coated particle composition |
US5532130A (en) | 1993-07-20 | 1996-07-02 | Dyad Pharmaceutical Corporation | Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5614621A (en) | 1993-07-29 | 1997-03-25 | Isis Pharmaceuticals, Inc. | Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents |
US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
US5808036A (en) | 1993-09-01 | 1998-09-15 | Research Corporation Technologies Inc. | Stem-loop oligonucleotides containing parallel and antiparallel binding domains |
WO1995006731A2 (en) | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
JP3484197B2 (en) | 1993-09-03 | 2004-01-06 | アイシス・ファーマシューティカルス・インコーポレーテッド | Amine derivatized nucleosides and oligonucleosides |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
GB9320782D0 (en) | 1993-10-08 | 1993-12-01 | Univ Leeds Innovations Ltd | Stabilising of proteins on solution |
JPH09504297A (en) | 1993-10-27 | 1997-04-28 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | 2'-amide and 2'-peptide modified oligonucleotides |
US6060456A (en) | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
NZ277616A (en) | 1993-11-16 | 1997-12-19 | Genta Inc | Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphate internucleosidyl linkages |
US20030130324A1 (en) | 1993-11-19 | 2003-07-10 | Johnston W. Mcavoy | Method for preventing or controlling cataract |
WO1995016466A1 (en) | 1993-12-17 | 1995-06-22 | The Ohio State University | Antisense oligonucleotides to suppress eicosanoid formation |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
CA2181546A1 (en) | 1994-02-18 | 1995-08-24 | Robert E. Kilkuskie | Oligonucleotides with anti-respiratory syncytial virus activity |
US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
US5646126A (en) | 1994-02-28 | 1997-07-08 | Epoch Pharmaceuticals | Sterol modified oligonucleotide duplexes having anticancer activity |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5777153A (en) | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5591721A (en) | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
US5681940A (en) | 1994-11-02 | 1997-10-28 | Icn Pharmaceuticals | Sugar modified nucleosides and oligonucleotides |
US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
US5767099A (en) | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
US5948767A (en) | 1994-12-09 | 1999-09-07 | Genzyme Corporation | Cationic amphiphile/DNA complexes |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
AUPN166195A0 (en) | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
US5674683A (en) | 1995-03-21 | 1997-10-07 | Research Corporation Technologies, Inc. | Stem-loop and circular oligonucleotides and method of using |
AU5545596A (en) | 1995-04-28 | 1996-11-18 | Medtronic, Inc. | Intraparenchymal infusion catheter system |
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
US6221911B1 (en) | 1995-06-07 | 2001-04-24 | Karo Bio Ab | Uses for thyroid hormone compounds or thyroid hormone-like compounds |
US5851548A (en) | 1995-06-07 | 1998-12-22 | Gen-Probe Incorporated | Liposomes containing cationic lipids and vitamin D |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
WO1996040964A2 (en) | 1995-06-07 | 1996-12-19 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
JP4338106B2 (en) | 1995-06-07 | 2009-10-07 | ライフ テクノロジーズ コーポレーション | Peptide enhanced cationic lipid transfection |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
AU7286696A (en) | 1995-10-13 | 1997-05-07 | F. Hoffmann-La Roche Ag | Antisense oligomers |
US5734041A (en) | 1995-10-20 | 1998-03-31 | Mcgill University | Preparation of chiral phosphorothioate oligomers |
US5705621A (en) | 1995-11-17 | 1998-01-06 | Isis Pharmaceuticals, Inc. | Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same |
US6344436B1 (en) | 1996-01-08 | 2002-02-05 | Baylor College Of Medicine | Lipophilic peptides for macromolecule delivery |
US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
US6331617B1 (en) | 1996-03-21 | 2001-12-18 | University Of Iowa Research Foundation | Positively charged oligonucleotides as regulators of gene expression |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US5735814A (en) | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US6444806B1 (en) | 1996-04-30 | 2002-09-03 | Hisamitsu Pharmaceutical Co., Inc. | Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US6506564B1 (en) | 1996-07-29 | 2003-01-14 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
US5789416B1 (en) | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
FR2755976B1 (en) | 1996-11-15 | 1999-01-15 | Idm Immuno Designed Molecules | NOVEL COMPLEXES OF NUCLEIC ACIDS AND POLYMER SUBSTITUTED BY RESIDUES CAUSING THE DESTABILIZATION OF CELL MEMBRANES |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US7789841B2 (en) | 1997-02-06 | 2010-09-07 | Exogen, Inc. | Method and apparatus for connective tissue treatment |
US5955594A (en) | 1997-04-30 | 1999-09-21 | Mishra; Lopa | Nucleic acids encoding proteins for early liver development |
EP1027033B1 (en) | 1997-05-14 | 2009-07-22 | The University Of British Columbia | High efficiency encapsulation of nucleic acids in lipid vesicles |
JP2002510319A (en) | 1997-07-01 | 2002-04-02 | アイシス・ファーマシューティカルス・インコーポレーテッド | Compositions and methods for delivery of oligonucleotides through the gastrointestinal tract |
AU741546B2 (en) | 1997-07-24 | 2001-12-06 | Perseptive Biosystems, Inc. | Conjugates of transporter peptides and nucleic acid analogs, and their use |
ES2279580T3 (en) | 1997-09-15 | 2007-08-16 | Genetic Immunity, Llc | COMPOSITIONS FOR MANAGING GENES TO SKIN CELLS THAT PRESENT ANTIGENS. |
US6028183A (en) | 1997-11-07 | 2000-02-22 | Gilead Sciences, Inc. | Pyrimidine derivatives and oligonucleotides containing same |
US6432963B1 (en) | 1997-12-15 | 2002-08-13 | Yamanouchi Pharmaceutical Co., Ltd. | Pyrimidine-5-carboxamide derivatives |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AU1682699A (en) | 1997-12-25 | 1999-07-19 | Japan Tobacco Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
US6020475A (en) | 1998-02-10 | 2000-02-01 | Isis Pharmeuticals, Inc. | Process for the synthesis of oligomeric compounds |
WO1999054459A2 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
EP1469009A2 (en) | 1998-05-21 | 2004-10-20 | Isis Parmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
US20040241845A1 (en) | 1998-05-22 | 2004-12-02 | Luc Desgroseillers | Mammalian staufen and use thereof |
US6096875A (en) | 1998-05-29 | 2000-08-01 | The Perlein-Elmer Corporation | Nucleotide compounds including a rigid linker |
US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
JP2002520038A (en) | 1998-07-20 | 2002-07-09 | アイネックス ファーマシューティカルズ コーポレイション | Liposome encapsulated nucleic acid complex |
US6271358B1 (en) | 1998-07-27 | 2001-08-07 | Isis Pharmaceuticals, Inc. | RNA targeted 2′-modified oligonucleotides that are conformationally preorganized |
US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
US20040009938A1 (en) | 1998-08-07 | 2004-01-15 | Muthiah Manoharan | Methods of enhancing renal uptake of oligonucleotides |
US6335437B1 (en) | 1998-09-07 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Methods for the preparation of conjugated oligomers |
US6344323B1 (en) | 1998-09-16 | 2002-02-05 | Vitagenix, Inc. | Compositions and methods for inhibiting cox-2 expression and treating cox-2 associated disorders by using cox-2 antisense oligonucleotides |
US6020483A (en) | 1998-09-25 | 2000-02-01 | Nexstar Pharmaceuticals, Inc. | Nucleoside modifications by palladium catalyzed methods |
US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
US6328765B1 (en) | 1998-12-03 | 2001-12-11 | Gore Enterprise Holdings, Inc. | Methods and articles for regenerating living tissue |
US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
KR100664625B1 (en) | 1998-12-14 | 2007-01-04 | 유니버시티 오브 마이애미 | Connective Tissue Growth Factor Fragments and Methods and Uses Thereof |
US6455586B1 (en) | 1998-12-15 | 2002-09-24 | Leonard L. Kaplan | Topical immunomodulating compositions for treatment of aids, Hepatitis B & C, other infectious diseases, and cancer |
DE60021700T2 (en) | 1999-01-27 | 2006-06-01 | Becker, David, Dr., Abbots Langley | FORMULATIONS CONTAINING ANTISENSE NUCLEOTIDE SPECIFIC FOR CONNEXINE |
DE19956568A1 (en) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Method and medicament for inhibiting the expression of a given gene |
US6465628B1 (en) | 1999-02-04 | 2002-10-15 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
US6207819B1 (en) | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
CN1273478C (en) | 1999-02-12 | 2006-09-06 | 三共株式会社 | Novel nucleosides and oligonucleotide analogues |
EP1156812A4 (en) | 1999-02-23 | 2004-09-29 | Isis Pharmaceuticals Inc | Multiparticulate formulation |
US6121437A (en) | 1999-03-16 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Phosphate and thiophosphate protecting groups |
US20020049173A1 (en) | 1999-03-26 | 2002-04-25 | Bennett C. Frank | Alteration of cellular behavior by antisense modulation of mRNA processing |
US6706491B1 (en) | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6033910A (en) | 1999-07-19 | 2000-03-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of MAP kinase kinase 6 expression |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
GB9925459D0 (en) | 1999-10-27 | 1999-12-29 | Plant Bioscience Ltd | Gene silencing |
JP2001206899A (en) | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | HUMAN MONOCLONAL ANTIBODY AGAINST TGF-beta II TYPE RECEPTOR AND MEDICINAL USE THEREOF |
US20040072785A1 (en) | 1999-11-23 | 2004-04-15 | Wolff Jon A. | Intravascular delivery of non-viral nucleic acid |
DE10160151A1 (en) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
US7098030B2 (en) | 1999-12-31 | 2006-08-29 | Mirus Bio Corporation | Polyampholytes for delivering polyions to a cell |
US20050032733A1 (en) * | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
JP2003526367A (en) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | RNA interference method and RNA interference composition |
PT1309726E (en) | 2000-03-30 | 2010-03-08 | Whitehead Biomedical Inst | Rna sequence-specific mediators of rna interference |
US7108721B2 (en) | 2000-05-11 | 2006-09-19 | Massachusetts Institute Of Technology | Tissue regrafting |
AU2001276934A1 (en) | 2000-07-18 | 2002-02-05 | Joslin Diabetes Center Inc. | Methods of modulating fibrosis |
AU2001273574A1 (en) | 2000-07-24 | 2002-02-05 | Krenitsky Pharmaceuticals Inc. | Substituted 5-alkynyl pyrimidines having neurotrophic activity |
US6346416B1 (en) | 2000-08-29 | 2002-02-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of HPK/GCK-like kinase expression |
US6794137B2 (en) | 2000-09-08 | 2004-09-21 | New York University | Gene markers useful for detecting skin damage in response to ultraviolet radiation |
US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
AU2001291019A1 (en) | 2000-09-15 | 2002-03-26 | Genvec, Inc. | Method of modulating neovascularization |
US20020081736A1 (en) | 2000-11-03 | 2002-06-27 | Conroy Susan E. | Nucleic acid delivery |
US20020132788A1 (en) | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
DK2813582T3 (en) | 2000-12-01 | 2017-07-31 | Max-Planck-Gesellschaft Zur Förderung Der Wss E V | Small RNA molecules that mediate RNA interference |
FR2818642B1 (en) | 2000-12-26 | 2005-07-15 | Hoechst Marion Roussel Inc | NOVEL DERIVATIVES OF PURINE, PROCESS FOR PREPARING THEM, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND THEIR NEW USE |
CA2433680A1 (en) | 2000-12-28 | 2002-08-01 | Gregory M Arndt | Double-stranded rna-mediated gene suppression |
DE10100127A1 (en) | 2001-01-03 | 2002-10-02 | Henkel Kgaa | Procedure for determining the homeostasis of the skin |
US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7044945B2 (en) | 2001-03-30 | 2006-05-16 | Sand Bruce J | Prevention of regression in thermal ciliary muscle tendinoplasty |
WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
GB0111279D0 (en) * | 2001-05-10 | 2001-06-27 | Nycomed Imaging As | Radiolabelled liposomes |
US20070032441A1 (en) | 2001-05-18 | 2007-02-08 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) |
US20070173473A1 (en) | 2001-05-18 | 2007-07-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
US20050239731A1 (en) | 2001-05-18 | 2005-10-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA) |
AU2004266311B2 (en) | 2001-05-18 | 2009-07-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
CA2790034A1 (en) | 2001-06-21 | 2003-01-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
US20050019915A1 (en) | 2001-06-21 | 2005-01-27 | Bennett C. Frank | Antisense modulation of superoxide dismutase 1, soluble expression |
DE10131458A1 (en) | 2001-06-29 | 2003-01-09 | Aventis Pharma Gmbh | Process for the identification of connections for the therapy of aging processes of the cardiovascular system |
US20030158403A1 (en) | 2001-07-03 | 2003-08-21 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
DE10133858A1 (en) | 2001-07-12 | 2003-02-06 | Aventis Pharma Gmbh | Synthetic double-stranded oligonucleotides for targeted inhibition of gene expression |
AU2002329667A1 (en) | 2001-07-30 | 2003-02-17 | Uta Griesenbach | Specific inhibition of gene expression by small double stranded rnas |
US20030113816A1 (en) | 2001-09-18 | 2003-06-19 | Weitz Stephen L. | Methods of assaying connective tissue growth factor |
AU2002343475A1 (en) | 2001-10-03 | 2003-04-14 | Selective Genetics, Inc. | Traversal of nucleic acid molecules through a fluid space and expression in repair cells |
CN1608133A (en) | 2001-10-26 | 2005-04-20 | 里伯药品公司 | Use of a double-stranded ribonucleic acid for treating an infection with a positivestrand rna-virus |
CN1604783A (en) | 2001-10-26 | 2005-04-06 | 里伯药品公司 | Drug for treating a fibrotic disease through rna interfence |
US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
IL161733A0 (en) | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
JP2005519881A (en) | 2001-12-11 | 2005-07-07 | ファイブローゲン、インコーポレーテッド | How to suppress eye processes |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
EP2213737B1 (en) | 2002-02-01 | 2012-11-07 | Life Technologies Corporation | Double-stranded oligonucleotides |
PT1470144E (en) | 2002-02-01 | 2009-02-10 | Univ Mcgill | Oligonucleotides comprising alternating segments and uses thereof |
US20030166282A1 (en) | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
AU2003216255A1 (en) | 2002-02-20 | 2003-09-09 | Ribozyme Pharmaceuticals, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US6923833B2 (en) | 2002-04-09 | 2005-08-02 | Ray C. Wasielewski | Biologically reabsorbable acetabular constraining components and materials for use with a hip replacement prosthesis and bioreabsorbable materials to augment hip replacement stability and function |
US20050222061A1 (en) | 2002-04-18 | 2005-10-06 | Schulte Ralf W | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
US20040014957A1 (en) | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
FR2840217B1 (en) | 2002-06-03 | 2005-06-24 | Oreal | COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE DOUBLE-STRANDED RNA OLIGONUCLEOTIDE (DSRNA) AND USES THEREOF |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
EP1857547B2 (en) | 2002-08-05 | 2020-12-02 | Silence Therapeutics GmbH | Further novel forms of interfering RNA molecules |
DE10238298A1 (en) | 2002-08-21 | 2004-03-04 | Beiersdorf Ag | Use of antisense oligonucleotides for the treatment of degenerative skin symptoms |
EP1546344A4 (en) | 2002-09-18 | 2007-10-03 | Isis Pharmaceuticals Inc | Efficient reduction of target rna's by single- and double-stranded oligomeric compounds |
EP1556402B1 (en) | 2002-09-25 | 2011-06-22 | University of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
US20050008617A1 (en) | 2002-09-28 | 2005-01-13 | Massachusetts Institute Of Technology | Compositions and methods for delivery of short interfering RNA and short hairpin RNA |
AU2003284323A1 (en) | 2002-10-18 | 2004-05-04 | Alnylam Pharmaceuticals Inc | Double-stranded rna structures and constructs, and methods for generating and using the same |
US7309361B2 (en) | 2002-10-23 | 2007-12-18 | Wasielewski Ray C | Biologic modular tibial and femoral component augments for use with total knee arthroplasty |
AU2003304386A1 (en) | 2002-10-30 | 2005-02-25 | The Center For Blood Research, Inc. | Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
KR20120038546A (en) | 2002-11-01 | 2012-04-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Compositions and methods for sirna inhibition of hif-1 alpha |
ES2334125T3 (en) | 2002-11-04 | 2010-03-05 | University Of Massachusetts | SPECIFIC ARN INTERFERENCE OF ALELOS. |
US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
DE10254214A1 (en) | 2002-11-20 | 2004-06-09 | Beiersdorf Ag | Oligoribonucleotides for the treatment of degenerative skin symptoms by RNA interference |
EP1585756B1 (en) | 2002-11-26 | 2010-04-21 | University of Massachusetts | Delivery of sirnas |
WO2004065600A2 (en) | 2003-01-17 | 2004-08-05 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference by palindromic or modified rna molecules |
DE10302421A1 (en) | 2003-01-21 | 2004-07-29 | Ribopharma Ag | New double-stranded interfering RNA, useful for inhibiting hepatitis C virus, has one strand linked to a lipophilic group to improve activity and eliminate the need for transfection auxiliaries |
JP2006516288A (en) | 2003-01-21 | 2006-06-29 | アーケミックス コーポレイション | Aptamer therapeutics useful in ophthalmic drug therapy |
AU2004211949A1 (en) | 2003-02-05 | 2004-08-26 | University Of Massachusetts | RNAi targeting of viruses |
EP1592791A2 (en) * | 2003-02-10 | 2005-11-09 | National Institute of Advanced Industrial Science and Technology | Regulation of gene expression by dna interference |
US20040162235A1 (en) | 2003-02-18 | 2004-08-19 | Trubetskoy Vladimir S. | Delivery of siRNA to cells using polyampholytes |
US20040167090A1 (en) | 2003-02-21 | 2004-08-26 | Monahan Sean D. | Covalent modification of RNA for in vitro and in vivo delivery |
US20050026286A1 (en) | 2003-03-05 | 2005-02-03 | Jen-Tsan Chi | Methods and compositions for selective RNAi mediated inhibition of gene expression in mammal cells |
US6962331B2 (en) | 2003-03-06 | 2005-11-08 | Canon Kabushiki Kaisha | Sheet stacking apparatus |
EP1605978B1 (en) | 2003-03-07 | 2010-09-01 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
WO2004090105A2 (en) | 2003-04-02 | 2004-10-21 | Dharmacon, Inc. | Modified polynucleotides for use in rna interference |
AU2004233092C9 (en) | 2003-04-17 | 2010-10-28 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
WO2004099372A2 (en) | 2003-05-01 | 2004-11-18 | University Of Florida | Anti-scarring ribozymes and methods |
US20060178327A1 (en) | 2003-05-30 | 2006-08-10 | Yeung Wah Hin A | Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro |
US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
ES2864206T3 (en) | 2003-06-02 | 2021-10-13 | Univ Massachusetts | Methods and compositions to improve the efficacy and specificity of RNAi |
US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
EP3604537B1 (en) | 2003-06-13 | 2021-12-08 | Alnylam Europe AG | Double-stranded ribonucleic acid with increased effectiveness in an organism |
US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
WO2005019430A2 (en) | 2003-08-22 | 2005-03-03 | Research Development Foundation | In vitro selection of aptamer beacons |
US20070167388A1 (en) | 2003-09-11 | 2007-07-19 | Universitätsklinikum Schleswig-Holstein Campus Lübeck | Nucleotide sequences promoting the trans-membrane transport of nucleic acids |
NZ592917A (en) | 2003-09-15 | 2012-12-21 | Protiva Biotherapeutics Inc | Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates |
US8258105B2 (en) | 2003-10-07 | 2012-09-04 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides optimized for kidney targeting |
WO2005051971A1 (en) | 2003-11-24 | 2005-06-09 | Canji, Inc. | Reduction of dermal scarring |
JP5838017B2 (en) | 2003-12-03 | 2015-12-24 | コーダ セラピューティクス, インコーポレイテッド | Antisense compounds targeted against connexins and methods of use thereof |
WO2005070970A1 (en) | 2004-01-16 | 2005-08-04 | Fibrogen, Inc. | Connective tissue growth factor signaling |
WO2005078094A2 (en) | 2004-02-06 | 2005-08-25 | Dharmacon, Inc. | Stabilized rnas as transfection controls and silencing reagents |
WO2005078096A2 (en) | 2004-02-09 | 2005-08-25 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
EP1731615A1 (en) | 2004-02-20 | 2006-12-13 | National Institute of Advanced Industrial Science and Technology | Cytoplasmic localization dna and rna |
WO2005085443A2 (en) | 2004-03-01 | 2005-09-15 | Massachusetts Institute Of Technology | Rnai-based therapeutics for allergic rhinitis and asthma |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US20080300147A1 (en) | 2004-03-26 | 2008-12-04 | Nasser Chegini | Detection and Treatment of Fibrotic Disorders |
WO2005096781A2 (en) | 2004-04-06 | 2005-10-20 | University Of Massachusetts | Methods and compositions for treating gain-of-function disorders using rna interference |
US20050265957A1 (en) | 2004-04-08 | 2005-12-01 | Monahan Sean D | Polymerized formamides for use in delivery of compounds to cells |
US8168600B2 (en) | 2004-04-23 | 2012-05-01 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
AU2005243410B2 (en) | 2004-05-14 | 2010-04-22 | Rosetta Genomics Ltd. | Micronas and uses thereof |
DK1753529T3 (en) | 2004-05-20 | 2013-11-11 | Eden Research Plc | Composition containing a hollow glucan particle or hollow cell wall particle encapsulating a terpene component, methods of preparing and using them |
AU2005252663B2 (en) | 2004-06-03 | 2011-07-07 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
EP2298892A3 (en) | 2004-08-23 | 2011-11-16 | Sylentis S.A.U. | Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs |
US20060211766A1 (en) | 2004-09-30 | 2006-09-21 | Kaplan Leonard L | Gelled immunomodulating topical compositions and a method of treating warts and other human papilloma virus skin infections |
AU2005311684A1 (en) | 2004-12-02 | 2006-06-08 | University Of Massachusetts | Glucose-transport related genes, polypeptides, and methods of use thereof |
US20100069620A1 (en) | 2004-12-02 | 2010-03-18 | Rxi Pharmaceuticals Corp. | Novel compositions of chemically modified small interfering rna |
EP1827436A4 (en) | 2004-12-15 | 2011-08-10 | Merck Sharp & Dohme | Inhibitors of akt activity |
WO2006066203A2 (en) | 2004-12-16 | 2006-06-22 | Alsgen, Llc | Small interfering rna (sirna) molecules for modulating superoxide dismutase (sod) |
US20060142228A1 (en) | 2004-12-23 | 2006-06-29 | Ambion, Inc. | Methods and compositions concerning siRNA's as mediators of RNA interference |
TWI386225B (en) | 2004-12-23 | 2013-02-21 | Alcon Inc | Rnai inhibition of ctgf for treatment of ocular disorders |
US20060171943A1 (en) | 2005-02-01 | 2006-08-03 | Amgen Inc. | Compositions and methods of treating fibrotic disorders |
EP1891217A2 (en) | 2005-05-27 | 2008-02-27 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina) |
JP5846711B2 (en) | 2005-06-09 | 2016-01-20 | メダ アーベー | Methods and compositions for the treatment of inflammatory diseases |
AU2006280600B2 (en) | 2005-08-17 | 2012-01-19 | Bioneer Corporation | Sirna-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
US20070161591A1 (en) | 2005-08-18 | 2007-07-12 | University Of Massachusetts | Methods and compositions for treating neurological disease |
WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
EP1948245B1 (en) | 2005-10-24 | 2011-10-05 | University of Massachusetts | Compositions and their uses for gene therapy of bone conditions |
FR2894582B1 (en) | 2005-12-12 | 2008-02-22 | Fabre Pierre Dermo Cosmetique | SIRNA ANTI MYOSINE VA AND DEPIGMENTATION OF THE SKIN |
AU2006325030B2 (en) | 2005-12-16 | 2012-07-26 | Cellectis | Cell penetrating peptide conjugates for delivering nucleic acids into cells |
US20120115923A1 (en) * | 2005-12-30 | 2012-05-10 | Intradigm Corporation | Sirna Compositions Promoting Scar-Free Wound Healing of Skin and Methods for Wound Treatment |
US7825099B2 (en) | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
EP1981543A1 (en) | 2006-01-23 | 2008-10-22 | Abbott Laboratories | Chemically modified polycation polymer for sirna delivery |
WO2007089607A2 (en) | 2006-01-26 | 2007-08-09 | University Of Massachusetts | Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same |
CA2644347C (en) | 2006-03-23 | 2017-05-30 | Santaris Pharma A/S | Small internally segmented interfering rna |
US8163708B2 (en) | 2006-04-03 | 2012-04-24 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotide |
EP2023939B1 (en) | 2006-05-05 | 2012-06-27 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of pcsk9 |
NZ572666A (en) | 2006-05-11 | 2010-11-26 | Alnylam Pharmaceuticals Inc | Compositions comprising double stranded rna and methods for inhibiting expression of the pcsk9 gene |
US20080152654A1 (en) | 2006-06-12 | 2008-06-26 | Exegenics, Inc., D/B/A Opko Health, Inc. | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
PL2040725T3 (en) | 2006-06-23 | 2014-08-29 | Engeneic Molecular Delivery Pty Ltd | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
US20080039415A1 (en) | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
CN102614528B (en) | 2006-08-18 | 2014-02-26 | 箭头研究公司 | Polyconjugates for in vivo delivery of polynucleotides |
US20080193443A1 (en) | 2006-10-30 | 2008-08-14 | Oxana Beskrovnaya | Methods and compositions for the treatment of polycystic diseases |
US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
EP2099497A2 (en) | 2006-12-05 | 2009-09-16 | Eyegate Pharma SA | Enhanced retinal delivery of a nucleic acid through iontophoresis |
US20090010948A1 (en) | 2006-12-15 | 2009-01-08 | The University Of Hong Kong | Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10 |
US8530436B2 (en) | 2007-01-29 | 2013-09-10 | Transderm, Inc. | Methods and compositions for transdermal delivery of nucleotides |
WO2008109353A1 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting map2k gene expression and uses thereof |
WO2008109105A2 (en) | 2007-03-06 | 2008-09-12 | Flagship Ventures | Methods and compositions for improved therapeutic effects with sirna |
WO2008124634A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
JP2010532360A (en) | 2007-07-02 | 2010-10-07 | ワイス・エルエルシー | Modulator of AXL for use in the treatment of bone disorders |
US9884899B2 (en) | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
CN101868251B (en) | 2007-08-06 | 2012-10-10 | 千寿制药株式会社 | Pharmaceutical containing HIF-1alpha alpha and HIF-2alpha alpha expression inhibitor |
EP2192920A4 (en) | 2007-08-21 | 2010-09-01 | Univ Virginia Commonwealth | Methods and compositions for treatment or prevention of radiation-induced fibrosis |
EP2193140B1 (en) | 2007-08-27 | 2016-11-02 | 1Globe Health Institute LLC | Compositions of asymmetric interfering rna and uses thereof |
CA2702028A1 (en) | 2007-10-02 | 2009-04-09 | Rxi Pharmaceuticals Corp. | Tripartite rnai constructs |
WO2009044392A2 (en) | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
DK2205737T3 (en) * | 2007-10-04 | 2013-05-21 | Santaris Pharma As | Micromirers |
US7935816B2 (en) | 2007-10-25 | 2011-05-03 | Gene Tools, Llc | Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo |
EP4074344A1 (en) | 2007-12-04 | 2022-10-19 | Arbutus Biopharma Corporation | Targeting lipids |
WO2009090639A2 (en) | 2008-01-15 | 2009-07-23 | Quark Pharmaceuticals, Inc. | Sirna compounds and methods of use thereof |
US10131904B2 (en) | 2008-02-11 | 2018-11-20 | Rxi Pharmaceuticals Corporation | Modified RNAi polynucleotides and uses thereof |
CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
CN102099029A (en) | 2008-07-09 | 2011-06-15 | 阿斯普瑞瓦国际公司 | Formulations for treating eye disorders |
US20110218334A1 (en) | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
US20110119781A1 (en) | 2008-07-15 | 2011-05-19 | Birgit Bramlage | Compositions and Methods for Inhibiting Expression of TGF-BETA Receptor Genes |
WO2010008582A2 (en) | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
CA2731779A1 (en) | 2008-07-24 | 2010-01-28 | Rxi Pharmaceuticals Corporation | Rnai constructs and uses therof |
ES2657696T3 (en) | 2008-08-25 | 2018-03-06 | Excaliard Pharmaceuticals, Inc. | Method to reduce healing during wound healing using antisense compounds targeting CTGF |
WO2010027830A2 (en) | 2008-08-25 | 2010-03-11 | Excaliard Pharmaceuticals, Inc. | Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases |
AU2009275387B2 (en) | 2008-08-25 | 2010-07-08 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
WO2010033248A2 (en) | 2008-09-22 | 2010-03-25 | Rxi Pharmaceuticals Corporation | Neutral nanotransporters |
US20110288147A1 (en) | 2008-09-22 | 2011-11-24 | Bob Dale Brown | Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop |
EP2346883B1 (en) | 2008-09-23 | 2016-03-23 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
US8822425B2 (en) | 2008-11-14 | 2014-09-02 | Antisense Pharma Gmbh | Dosage of oligonucleotides suitable for the treatment of tumors |
US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
WO2010065834A1 (en) | 2008-12-04 | 2010-06-10 | Opko Ophthalmics, Llc | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
AU2010249881B2 (en) | 2009-05-16 | 2015-01-22 | Agave Pharma, Incorporated | Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules |
WO2010151640A2 (en) * | 2009-06-24 | 2010-12-29 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease |
EP2486061A4 (en) | 2009-10-06 | 2013-08-28 | Angiochem Inc | Compositions and methods for the transport of therapeutic agents |
WO2011109248A1 (en) | 2010-03-02 | 2011-09-09 | Hapten Pharmaceuticals, Llc | Effective sensitizing dose of a gelled immunomodulating topical composition |
WO2011109698A1 (en) | 2010-03-04 | 2011-09-09 | Rxi Pharmaceuticals Corporation | Formulations and methods for targeted delivery to phagocyte cells |
WO2011119871A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Phrmaceuticals Corporation | Rna interference in ocular indications |
JP6060071B2 (en) | 2010-03-24 | 2017-01-11 | アールエックスアイ ファーマシューティカルズ コーポレーション | RNA interference in skin and fibrosis applications |
EP2550000A4 (en) * | 2010-03-24 | 2014-03-26 | Advirna Inc | Reduced size self-delivering rnai compounds |
WO2012040101A1 (en) | 2010-09-21 | 2012-03-29 | University Of Miami | Compositions and methods for inducing migration by dendritic cells and an immune response |
EP2651979B1 (en) | 2010-12-17 | 2019-08-28 | Neurimmune Holding AG | Human anti-sod1 antibodies |
WO2012106508A1 (en) | 2011-02-02 | 2012-08-09 | Pfizer Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
US20140072613A1 (en) | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
WO2014191493A1 (en) | 2013-05-28 | 2014-12-04 | Vib Vzw | Single domain antibodies against sod1 and their use in medicine |
SI3039146T1 (en) | 2013-08-27 | 2020-10-30 | Research Institute At Nationwide Children's Hospital | Products and methods for treatment of amyotrophic lateral sclerosis |
WO2015038892A1 (en) | 2013-09-13 | 2015-03-19 | Moderna Therapeutics, Inc. | Polynucleotide compositions containing amino acids |
CN113151180A (en) | 2013-12-02 | 2021-07-23 | 菲奥医药公司 | Immunotherapy of cancer |
JP6883987B2 (en) | 2013-12-04 | 2021-06-09 | フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. | Methods for wound healing procedures utilizing chemically modified oligonucleotides |
CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
CA2947619A1 (en) | 2014-05-01 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules |
KR20230037676A (en) | 2014-09-05 | 2023-03-16 | 피오 파마슈티칼스 코프. | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
WO2016090173A1 (en) | 2014-12-03 | 2016-06-09 | Rxi Pharmaceuticals Corporation | Methods for the treatment of alopecia areata utilizing gene modulation approaches |
WO2016161388A1 (en) | 2015-04-03 | 2016-10-06 | University Of Massachusetts | Fully stabilized asymmetric sirna |
ES2901455T3 (en) | 2015-04-03 | 2022-03-22 | Univ Massachusetts | Oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders |
ES2808750T3 (en) | 2015-04-03 | 2021-03-01 | Univ Massachusetts | Oligonucleotide compounds targeting huntingtin mRNA |
KR20180026739A (en) | 2015-07-06 | 2018-03-13 | 알엑스아이 파마슈티칼스 코포레이션 | A nucleic acid molecule targeting superoxide dismutase 1 (SOD1) |
US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
US20190029974A1 (en) | 2015-09-11 | 2019-01-31 | Rxi Pharmaceuticals Corporation | Methods for treating skin disorders and conditions utilizing haptens |
US20180251548A1 (en) | 2015-09-14 | 2018-09-06 | Compass Therapeutics Llc | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta |
US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
US20190117799A1 (en) | 2016-04-01 | 2019-04-25 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
JP7167059B2 (en) | 2017-04-19 | 2022-11-08 | フィオ ファーマシューティカルズ コーポレーション | Local delivery of nucleic acid compounds |
CN111201024A (en) | 2017-08-07 | 2020-05-26 | 菲奥医药公司 | Chemically modified oligonucleotides |
-
2009
- 2009-09-22 WO PCT/US2009/005251 patent/WO2010033248A2/en active Application Filing
- 2009-09-22 EP EP09789350A patent/EP2342340A1/en not_active Withdrawn
- 2009-09-22 CN CN201711334248.1A patent/CN108165548B/en active Active
- 2009-09-22 WO PCT/US2009/005247 patent/WO2010033247A2/en active Application Filing
- 2009-09-22 EP EP09789352A patent/EP2340309A2/en not_active Withdrawn
- 2009-09-22 US US13/120,341 patent/US10138485B2/en active Active
- 2009-09-22 EP EP17200910.2A patent/EP3336188B1/en active Active
- 2009-09-22 US US13/120,315 patent/US8664189B2/en active Active
- 2009-09-22 CA CA2753338A patent/CA2753338A1/en not_active Abandoned
- 2009-09-22 CN CN2009801464922A patent/CN102405286A/en active Pending
- 2009-09-22 US US13/120,342 patent/US8796443B2/en active Active
- 2009-09-22 CA CA3027780A patent/CA3027780A1/en active Pending
- 2009-09-22 AU AU2009293658A patent/AU2009293658A1/en not_active Abandoned
- 2009-09-22 WO PCT/US2009/005246 patent/WO2010033246A1/en active Application Filing
- 2009-09-22 CA CA2743981A patent/CA2743981C/en active Active
- 2009-09-22 JP JP2011527827A patent/JP2012502991A/en not_active Withdrawn
- 2009-09-22 EP EP15164722.9A patent/EP2949752B1/en active Active
- 2009-09-22 CA CA2746527A patent/CA2746527A1/en not_active Abandoned
- 2009-09-22 JP JP2011527828A patent/JP6209309B2/en active Active
- 2009-09-22 EP EP09789351.5A patent/EP2340310B1/en active Active
-
2011
- 2011-03-22 IL IL211863A patent/IL211863A0/en unknown
- 2011-03-23 US US13/069,780 patent/US10041073B2/en active Active
-
2013
- 2013-12-12 US US14/104,450 patent/US9303259B2/en active Active
-
2014
- 2014-05-15 US US14/278,900 patent/US9175289B2/en active Active
-
2015
- 2015-09-25 US US14/866,681 patent/US10774330B2/en active Active
-
2016
- 2016-02-11 US US15/041,738 patent/US9938530B2/en active Active
- 2016-03-04 JP JP2016042603A patent/JP6342929B2/en active Active
-
2018
- 2018-02-26 US US15/905,118 patent/US10815485B2/en active Active
- 2018-03-13 JP JP2018045202A patent/JP6849627B2/en active Active
- 2018-06-28 US US16/022,652 patent/US10876119B2/en active Active
- 2018-10-12 US US16/159,590 patent/US11396654B2/en active Active
-
2020
- 2020-07-21 US US16/934,864 patent/US20210147849A1/en active Pending
-
2021
- 2021-03-04 JP JP2021034250A patent/JP7397019B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080020990A1 (en) * | 2003-05-30 | 2008-01-24 | Nippon Shinyaku Co., Ltd. | Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same |
WO2005079533A2 (en) * | 2004-02-17 | 2005-09-01 | University Of Massachusetts | Methods and compositions for mediating gene silencing |
WO2005097992A2 (en) * | 2004-04-01 | 2005-10-20 | Dharmacon, Inc. | Modified polynucleotides for reducing off-target effects in rna interference |
WO2006019430A2 (en) * | 2004-04-20 | 2006-02-23 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
WO2006039656A2 (en) * | 2004-10-01 | 2006-04-13 | Novartis Vaccines And Diagnostics Inc. | Modified small interfering rna molecules and methods of use |
WO2006113679A2 (en) * | 2005-04-15 | 2006-10-26 | Board Of Regents, The University Of Texas System | Delivery of sirna by neutral lipid compositions |
WO2008036825A2 (en) * | 2006-09-22 | 2008-03-27 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
WO2009020344A2 (en) * | 2007-08-06 | 2009-02-12 | Postech Acad Ind Found | Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same |
WO2009078685A2 (en) * | 2007-12-18 | 2009-06-25 | Dong Ki Lee | Novel sirna structure for minimizing off-target effects and relaxing saturation of rnai machinery and the use thereof |
Non-Patent Citations (11)
Title |
---|
BROWN K. AND SAMARSKY D.: "RNAi off-targeting: Light at the end of the tunnel.", JOURNAL OF RNAI AND GENE SILENCING, vol. 2, no. 2, 2006, pages 175 - 177, XP002563015, ISSN: 1747-0854 * |
CZAUDERNA F. ET AL.: "Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells", NUCLEIC ACIDS RESEARCH, vol. 31, no. 11, 1 June 2003 (2003-06-01), pages 2705 - 2716, XP002404762, ISSN: 0305-1048 * |
DEBART F. ET AL.: "Chemical modifications to improve the cellular uptake of oligonucleotides", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 7, 2007, pages 727 - 737, XP002562043 * |
DYKXHOORN D.M. ET AL.: "The silent treatment: siRNAs as small molecule drugs", GENE THERAPY, vol. 13, 2006, pages 541 - 552, XP002562042 * |
ELBASHIR S.M. ET AL.: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494 - 498, XP002206451, ISSN: 0028-0836 * |
ELBASHIR S.M. ET AL.: "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", EMBO JOURNAL, vol. 20, no. 23, 3 December 2001 (2001-12-03), pages 6877 - 6888, XP002225998, ISSN: 0261-4189 * |
FEDOROV Y. ET AL.: "Off-target effects by siRNA can induce toxic phenotype", RNA,, vol. 12, no. 7, 1 July 2006 (2006-07-01), pages 1188 - 1196, XP002547706 * |
JACKSON A.L. ET AL.: "Position-specific chemical modification of siRNAs reduces off-target transcript silencing", RNA, vol. 12, 1 January 2006 (2006-01-01), pages 1197 - 1205, XP002558507 * |
KUBO TAKANORI ET AL.: "Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity", OLIGONUCLEOTIDES, vol. 17, no. 4, 1 December 2007 (2007-12-01), pages 445 - 464, XP002537984, ISSN: 1545-4576 * |
LEE HUI SUN ET AL.: "Contributions of 3'-overhang to the dissociation of small interfering RNAs from the PAZ domain: Molecular dynamics simulation study", JOURNAL OF MOLECULAR GRAPHICS AND MODELLING, vol. 25, no. 6, 9 February 2007 (2007-02-09), pages 784 - 793, XP005881341, ISSN: 1093-3263 * |
SHEN YU: "Advances in the development of siRNA-based therapeutics for cancer", IDRUGS, vol. 11, no. 8, August 2008 (2008-08-01), pages 572 - 578, XP002562041 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010033247A3 (en) | Reduced size self-delivering rnai compounds | |
WO2011056005A3 (en) | Novel sirna structure for minimizing off-target effects caused by antisense strands, and use thereof | |
EP2609198B8 (en) | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER | |
WO2011012316A3 (en) | Rna with a combination of unmodified and modified nucleotides for protein expression | |
WO2008137862A3 (en) | Methods of using mir34 as a biomarker for tp53 functional status | |
HK1200487A1 (en) | Silencing of csn5 gene expression using interfering rna rna csn5 | |
WO2014043289A3 (en) | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof | |
IL212461A0 (en) | E. coli mediated gene silencing of beta-catenin | |
WO2010048585A3 (en) | Oligomeric compounds and methods | |
WO2008078180A3 (en) | Materials and methods for the generation of transcripts comprising modified nucleotides | |
WO2011008730A3 (en) | Chemical modification of small hairpin rnas for inhibition of gene expression | |
EP2431465A4 (en) | Method for synthesis of double-stranded dna corresponding to rna, and method for amplification of the dna | |
EP2269026A4 (en) | Assay apparatuses, methods and reagents | |
SI2143792T1 (en) | Single-stranded cyclic RNA, and method of production thereof | |
BRPI1014906A2 (en) | document with sections, and, manufacturing process of it. | |
EP2518147A4 (en) | Diacylglycerole acyltranferase gene, and use thereof | |
WO2008152131A3 (en) | Rnai inhibition of alpha-enac expression | |
WO2009091972A3 (en) | Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof | |
EP2316934A4 (en) | Rna polymerase mutant with improved functions | |
WO2008151032A3 (en) | Arrays and methods comprising m. smithii gene products | |
WO2009108217A3 (en) | Compositions comprising k-ras sirna and methods of use | |
GB0805363D0 (en) | Novel NRPS-PKS gene cluster and its manipulation and utility | |
WO2006045591A3 (en) | Method and constructs for delivering double stranded rna to pest organisms | |
WO2007014077A3 (en) | Rnai modulation of the rho-a gene and uses thereof | |
PL2295563T3 (en) | Beta-amylase, gene coding therefor and manufacturing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980146492.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09789351 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2743981 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011527828 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 592372 Country of ref document: NZ Ref document number: 2009293658 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009789351 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009293658 Country of ref document: AU Date of ref document: 20090922 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13120342 Country of ref document: US |